Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
363 Results Found
FTC, HHS seek comment on generic drug shortages and competition
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting practices among group purchasing organizations and drug wholesalers to understand their potential impact on pricing and generic drug shortages.
AHA Statement on “Health Care Spending in the United States: Unsustainable for Patients, Employers, and Taxpayers”
The AHA shares comments on the topic of national health expenditures before the House Committee on Energy and Commerce Subcommittee on Health .
Cost-Plus Drug Pricing Models Gain Momentum, but Will They Last?
CVS Health plans to launch its CVS CostVantage and CVS Caremark TrueCost programs in 2025. CostVantage will define the drug cost and related reimbursement with contracted PBMs and payers, CVS noted in a statement.
President proposes congressional, federal action to lower drug costs
President Biden urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each year.
Administration actions target health care competition, lower drug costs
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote competition in health care and support lower prescription drug costs.
Broadlawns Medical Center | Iowa
Broadlawns Medical Center of Des Moines treats a diverse population of patients, addressing the medical, societal, and behavioral health needs of local citizens – from the greater Des Moines area – serving more than 72,757 patients in fiscal year 2022.
AHA Comments on the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
AHA comments on the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act.
CMS: Makers of selected drugs agree to participate in Medicare price negotiation
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in the program’s price negotiations, the Centers for Medicare & Medicaid Services announced.
FDA seeks comments on updated labeling guidance for biosimilar products
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar products.
CMS releases fact sheet on Medicare drug price negotiation process
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price Negotiation Program, its process for negotiating with the companies that make the drugs, opportunities for public input and key dates for implementation.